Representative images of Fluorodeoxyglucose PET ([18F]FDG-PET) images in a control subject (left) and a patient with advanced Alzheimer’s Disease (AD) (right). [18F]FDG-PET measures glucose metabolism from neurons and astrocytes and decreased cerebral [18F]FDG-PET signal is often interpreted as a sign of neurodegeneration. Areas of abnormal metabolism include posterior regions such as the posterior cingulate cortex and lateral parietal cortices. Also, there is decreased metabolism in lateral temporal cortices. Note how all these regions are normal in the control subject. Furthermore, note that primary sensory areas, such as the visual cortex and sensory-motor strip, are relatively spared in patients with AD. This helps nuclear medicine physicians identify the FDG-PET pattern.
More information on FDG-PET visual reads can be found in Nobili F, Arbizu J, Bouwman F, et al. Eur J Neurol. 2018;25(10):1201-1217.
Related content
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the leading cause of dementia worldwide, regardless of socioeconomic status.
Dementia is an umbrella term used to describe a state where an individual has lost the ability to carry out daily life activities independently because of cognitive impairment that is not due to an underlying psychiatric condition. Alzheimer’s disease (AD) refers to the abnormal presence of Aβ and tau proteins, which define AD among many other neurodegenerative diseases. Dementia -including dementia due to AD- is likely to be underestimated because of underdiagnosis and misdiagnosis.